AMB116457: An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

Published: 14-08-2013
Last updated: 22-04-2024

Primary: to assess the longterm safety and tolerability of ambrisentan 5mg in subjects with inoperable CTEPH. Secondary: to collect supportive efficacy data.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Pulmonary vascular disorders
Study type	Interventional

Summary

ID

NL-OMON38441

Source
ToetsingOnline

Brief title
AMB116457

Condition

- Pulmonary vascular disorders

Synonym
chronic thromboembolic pulmonary hypertension; CTEPH

Research involving
Human

Sponsors and support

Primary sponsor: GlaxoSmithKline BV
Source(s) of monetary or material Support: GlaxoSmithKline BV

Intervention

Keyword: ambrisentan, hypertension, pulmanary, thromboembolic

Outcome measures

Primary outcome

Adverse events.

Secondary outcome

6 minute walk test, WHO functional class, Borg CR10 scale, clinical worsening

of CTEPH, co-medication, NT-proBNP, SF-36 questionnaire.

Study description

Background summary

Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition characterized by thrombus organization, stenosis of pulmonary artery, and subsequent vascular remodeling in small unobstructed vessels, resulting in increased pulmonary vascular resistance, progressive pulmonary hypertension (PH) and right heart failure. CTEPH is associated with considerable morbidity and mortality.
The preferred treatment for CTEPH is surgical disobliteration of the arteries by pulmonary endarterectomy. The perioperative mortality is 5 to 10%. There are significant improvements in hemodynamics. However for some patients surgery is not an option. Management of these patients was previously supportive. Disease-modifying therapies used in other forms of pulmonary arterial hypertension have been utilized. There are no licensed treatments for CTEPH. Ambrisentan is a selective endotheline receptor antagonist licensed for the treatment of WHO FC II and III PH. Given that the histopathologic changes seen in CTEPH, the evidence that endotheline-1 levels are raised, and the clinical evidence (mainly uncontrolled) that a number of licensed PH treatments show efficacy in CTEPH, it is hypothesised that ambrisentan may provide benefit to patients with inoperable CTEPH.
This is an open-label extension study of the placebo controlled phase III study

with ambrisentan in inoperable patients with CTEPH (AMB115811).

Study objective

Primary: to assess the longterm safety and tolerability of ambrisentan 5mg in subjects with inoperable CTEPH.
Secondary: to collect supportive efficacy data.

Study design

Open label, long term extension to study AMB115811. Ambrisentan 5 mg daily. All subjects may continue in the extension study until one of the following conditions is met:
* The product is approved locally and made commercially available for use in inoperable CTEPH patients;
* Development for use in the CTEPH population is discontinued or product is not approved by the local regulatory authorities
* The investigator decides to discontinue the subject or subject decides to discontinue from the study.

Intervention

Treatment with ambrisentan.

Study burden and risks

Risk: Adverse effects of study medication.
Burden:
Monthly visits with blood draw (approx. 10 ml/occasion).
Every 3 months: Urine test, pregnancy test, physical examination, 6 minute walk test.
ECG every 6 months.
SF-36 questionnaire every 3 months during 1st 18 months.

Contacts

Public
GlaxoSmithKline BV

Huis ter Heideweg 62
Zeist 3705 LZ
NL
Scientific
GlaxoSmithKline BV

Huis ter Heideweg 62
Zeist 3705 LZ
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

* Male and female patients with inoperable CTEPH, who have completed the week 16 visit of AMB115811 or who prematurely withdrew for whatever reason. Capable of giving informed consent.

Exclusion criteria

* Pregnancy or breastfeeding. Non compliance with contraceptive measures from AMB115811.
* Subjects who are to enter another clinical trial or be treated with another investigational product after exiting Study AMB115811.

Study design

Design

Study phase:	3
Study type:	Interventional
Masking:	Open (masking not used)

Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	10-07-2014
Enrollment:	5
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Volibris
Generic name:	ambrisentan
Registration:	Yes - NL outside intended use

Ethics review

Approved WMO

Date:	14-08-2013
Application type:	First submission
Review commission:	METC Amsterdam UMC

Approved WMO

Date:	16-12-2013
Application type:	First submission
Review commission:	METC Amsterdam UMC

Approved WMO

Date:	11-02-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Approved WMO

Date:	31-07-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Approved WMO

Date:	03-04-2015
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2012-001642-17-NL
CCMO	NL45342.029.13
Other	www.clinicaltrials.gov; registratienummer n.n.b.